Pfizer (PFE) heads into its Morgan Stanley Global Healthcare Conference presentation on 14 September with investors watching ...

Pfizer (NYSE:PFE) has signed a co-development and license deal with Medicus Pharma for an early clinical-stage ...

Pfizer PFE faces a number of structural headwinds, ranging from patent expirations and declining COVID-19 revenues to pricing ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. BRAFTOVI's Phase 3 success and PADCEV + ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. After winning a broader FDA label for metastatic castration-resistant prostate cancer (mCRPC ...

Pfizer PFE stock has risen 8.6% in the past three months as investors have gained confidence in the company’s ability to ...

Pfizer is making a renewed push into oncology, even as significant long-term challenges cast a shadow over its future. A major research and development agreement aims to bolster its cancer drug ...

Pfizer PFE has committed significant resources toward the development of treatments in the fields of oncology, metabolic disease and vaccines. It is also scaling artificial intelligence across R&D and ...